Survey
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project
Thin Blood Department of Clinical Toxicology and Pharmacology Newcastle Mater Hospital Case 1 • 37 year old male • Presented to JHH Emergency Department • Drug overdose – 120 mg warfarin • Activated charcoal • Bloods sent • Transfer to MMH after d/w Toxicology Background • Precipitating incident : – Brother suicided recently – Planned overdose for 2 days • Psychiatric background : – No previous deliberate self harm – Amphetamine dependence Medical History • Endocarditis 2º to IVDU • Valve replacement x 2 – mitral and aortic valve replacements – St. Judes : bileaflet – Complicated by AMI and CVA • Lifelong anticoagulation • Nil attendance with cardiology follow up On arrival • • • • • • HR 80 BP 144/88 Temp 36.2 Alert and Cooperative No bruising or evidence of bleeding Dysarthric with mild cognitive impairment HSD, metallic sounds No signs of cardiac failure Initial Management • INR 2.0 • Appropriate Management ? – FFP – Vitamin K Initial Management • Haematology consult – 4 units FFP – 10 mg vitamin K IVI • Neurological observation • 2-3 daily INR INR Results Date/Time 9/12 2030 10/12 0000 10/12 0400 10/12 1300 INR 2.0 1.9 1.4 1.2 Vitamin K 10 mg IVI 4 Units FFP INR Results Date/Time 10/12 INR APTT 2015 11/12 0745 11/12 1540 12/12 0805 1.3 1.9 2.2 2.6 63 63 60 Heparin 5,000 U Infusion 1000 U/hr INR Results Date/Time 12/12 0805 13/12 0740 1412 0805 15/12 1035 INR 2.6 2.2 2.1 2.4 APTT 60 45 46 Heparin ceased Warfarin recommenced, normal dose 5 mg/d Time course of INR 3 INR 2 Heparin Ceased 1 Warfarin Restarted FFP Heparin Vit K 0 0 1 2 3 Time (days) 4 5 6 Optimal Management - Issues • • • • Perfect dose of vitamin K ! Normalised INR with FFP; then therapeutic Required heparinisation for 2 days No active bleeding Case 2 • 43 year old male • Drug overdose 1 hour previously – 25 x 5 mg warfarin – 40 x 5 mg oxycodone • Multiple lacerations to left forearm • Vomited in transit to MMH Background • Precipitating incident : – Argument with wife, asked to leave • Psychiatric background : – Narcotic dependence; 7 year history – No previous deliberate self harm Medical History • Thromboembolic disease – Pulmonary embolus (definite diagnosis) – Recurrent DVTs, mainly on symptoms – Not thrombophilic ; testing negative • Chronic back pain • Gastro-oesophageal reflux • Hypertension On arrival • • • • • HR 66 BP 155/91 RR 14 Decreased LOC, just rousable Small and sluggish pupils Multiple lacerations on left forearm Nil else on examination Initial Management • Response to naloxone; infusion commenced (2mg/50 mL) at 15 mL/hr • Lacerations sutured • Bloods sent including Group + Save Initial Management 2 • INR 3.7 • Appropriate management ? – FFP – Vitamin K Initial Management 2 • Haematology consult – 6 units FFP – 10 mg vitamin K IVI • Neurological observation • 2-3 daily INR Progress - Day 2 • Clinical : no bleeding complications • Naloxone infusion continued • INR Results Date/Time 23/02 INR 1930 24/02 0325 24/02 1105 24/02 2030 3.7 1.3 1.3 1.2 Progress - Day 3 • Haematology review : – commenced on daily enoxaparine 1 mg/kg – TED stockings – Daily INR • Naloxone infusion ceased • Psychiatric assessment • Drug and Alcohol review Progress - Day 2 - 6 • Day 4 : Warfarin recommenced 14 mg daily (normal dose) • Day 5 : Enoxaparin increased to twice daily Date/Time D2 D3 D5 D6 INR 1.3 1.1 1.0 1.1 Warfarin recommenced Progress - Day 5 - 12 • Transferred to inpatient psychiatric unit • Normal warfarin dose • Continue enoxaparin until therapeutic INR Date/Time D8 D10 D11 D12 INR 1.2 1.5 1.5 1.6 Time course of INR 4 INR 3 2 1 Vitamin K Warfarin 0 0 2 4 6 8 Time (days) 10 12 14 Comments / Problems • What dose of vitamin K is appropriate ? • Patient still has a non-therapeutic INR two weeks after vitamin K Case 3 • 44 year old male • Drug overdose 3 hours previously – 150 mg warfarin – 2 g chlorpromazine • Aortic valve replacement 8 years previously • Asthma, OCD, pathological gambling Initial Assessment • • • • Drowsy but easily roused Normal observations No active bleeding or bruising INR 1.9 Plan • No haematology consult • Q3H INR • Research: – Intermittent factor levels – Serial warfarin determination • Vitamin K 1 mg if INR > 5.0 30 Warfarin INR INR or Warfarin Concentration (mg/L) Vitamin K 25 20 100% 15 Factor II Factor VII Factor IX 10 5 0 0 1 2 3 4 Time (days) 5 6 7 8 Excessive Anticoagulation • Situation : – Therapeutic dose : drug interaction, other – Acute Overdose • Thromboembolic Risk – None – Low-medium : previous DVT/PE/thrombophilia – High : mechanical heart valve Acute Overdose - not own • No thromboembolic risk • Treatment : – – – – vitamin K 5 - 10 mg IVI or oral FFP if actively bleeding Monitor INR Straight-forward • Complicated in cases of long-acting agents Overdose or Therapeutic Low-Medium Risk of Thromboembolism • Requirements : – decrease INR to prevent bleeding complications – can tolerate normalisation of INR for a period – need to be restarted and reach therapeutic INR • Issues : – Use of FFP – Use of vitamin K and dose – requirement for heparin and hospital stay Overdose or Therapeutic High Risk of Thromboembolism • Requirements : – decrease INR to prevent bleeding complications – risk of thromboembolic complications with normalisation of INR for any period of time • Issues : – Use of FFP – Use of vitamin K and dose – requirement for heparin and hospital stay Increased INR & Risk of bleeding • INR > 4.5, 5.0 and 6.0 • Exponential increase in bleeding – Br J. Haem 1998 (Guidelines); – Cannegieter NEJM 1995 – Pal Increased INR and Risk of bleeding • Palareti et al. • Prospective cohort study – 2745 patients on anticoagulants – F/U for a mean of 267 days – temporally related INRs • Multivariate analysis: patients with an INR > 4.5 had an increased risk of bleeding, RR 5.96 (3.689.67, p<0.0001), compared to INR < 4.5 Increased INR and Risk of bleeding • INR > 6.0 : Hylek Arch Intern Med 2000 – Abnormal bleeding 8.8% – Major bleeding 4.4% cf. 0% INR < 6.0 (P<0.001) • INR > 7.0 : Panneerselvam Br J Haem 1998 – Total bleeding 12/31 vs. 13/100 O.R. 5.4 – 5 major bleeds vs. none Increased INR and Risk of bleeding • INR > 8.0 Baglin Blood Rev 1998; – 12.9% major bleeding Murphy Clin Lab Haematol 1998 • Severe anticoagulation : Hung Br J Haematol 2000 – INR > 9.5 – APTT ratio > 2.0 – Required additional vitamin K doses Low INR and Risk of Embolism for High risk patients • Patients with mechanical heart valves • Risk of embolism rises with INR < 2.5 • Sub-groups with higher risk : – > 70 years age – Both > mitral > aortic – Caged ball/disk > tilting disk > bileaflet Therapeutic Options • Fresh frozen plasma • Vitamin K – oral – intravenous • Heparinisation – intravenous unfractionated – low molecular weight Fresh Frozen Plasma • Major bleeding • Minor bleeding; risk groups eg. age • Guidelines Br J Haematol 1998 Vitamin K ? Appropriate dose • Oral vitamin K • RCT : Vit K, 1 mg vs. placebo (INR 4.5 - 10) – more rapid decrease in INR; 56% vs. 20 % with INR between 1.8 - 3.2 after 24 hrs (p< 0.001) – fewer patients had bleeding episodes during follow up 4% vs. 17% p = 0.05 ( 3 months) – Crowther Lancet 2000 Vitamin K ? Appropriate dose • Intravenous vitamin K; RCT : INR > 6.0 – asymptomatic 0.5 mg vs. 1 mg – symptomatic 1 mg vs. 2 mg • INR fallen to 5 - 5.5 in all 3 groups by 6 hrs – Optimal INR (2-4) in 67% receiving 0.5 mg, but only in 33% receiving 1 or 2 mg – Over-correction in 16% (0.5 mg); 50% (1-2 mg) – no adverse effects • Hung. Br J Haematol 2000 Vitamin K - Suggested dosing • INR > 5.0 ; asymptomatic, mild bleeding – 0.5 mg IV – repeat INR 6 - 12 hours – titrate as required • INR > 9.5; APTT ratio > 2.0 – 1 mg IV – repeat 6 hours – more likely to require repeat doses Vitamin K